Top Markets
#1 STAU STAU +197.40%
#2 Islamic Coin Islamic Coin +157.11%
#3 Venom Venom +76.70%
#4 Backpack Backpack +33.57%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +32.06%
#6 Nillion Nillion +30.07%
#7 Bitway Bitway +26.99%
#8 Falcon Finance Falcon Finance +23.56%
#9 Sonic (prev. FTM) Sonic (prev. FTM) +22.81%
#10 Epic Chain Epic Chain +17.43%
Coin of the day
STAU STAU
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Novartis AG Novartis AG

Novartis AG

NOVN
शेयरों में रैंक #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
शेयर मूल्य
$149.90
अंतिम समन्वयन: 2026-09-18
मार्केट कैप
$284.92B
बदलाव (1 दिन)
-0.66%
बदलाव (1 वर्ष)
21.93%
देश
CH
व्यापार Novartis AG (NOVN)

श्रेणी

Healthcare
Novartis AG (NOVN) के लिए P/S अनुपात
February 2026 को P/S अनुपात TTM: 5.52
Novartis AG की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/S अनुपात (TTM) 5.52 है। 2026 के अंत में, कंपनी का P/S अनुपात 0 था।
Novartis AG के लिए 2026 से 2026 तक P/S अनुपात का इतिहास
हर वर्ष के अंत में P/S अनुपात
वर्ष P/S अनुपात परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए P/S अनुपात
कंपनी P/S अनुपात P/S अनुपात में अंतर देश
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
13.45 143.63%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.55 18.72%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.18 30.08%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 -15.62%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
5.39 -2.41%
US